gout
Ironwood returns US Zurampic rights to AstraZeneca, announces operational cuts
August 7, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Ironwood, Zurampic, gout, pharma
Ironwood Pharmaceuticals has revealed that it has taken the decision to hand the rights for gout therapy Zurampic (lesinurad) back …
FDA approves Ironwood’s combination gout treatment
August 22, 2017Manufacturing and Production, Sales and Marketing Duzallo, FDA, Ironwood Pharmaceuticals, gout, life sciences, pharma, pharmaceuticals
Ironwood Pharmaceuticals has announced that the FDA has approved its drug Duzallo for the treatment of hyperuricemia associated with gout …
Potential treatment for opioid withdrawal discovered
February 1, 2017Medical Communications, Research and Development University of Calgary, gout, opioid
Researchers from the University of Calgary have found that medication used to treat gout could also lessen the side-effects experienced …
AstraZeneca licenses gout drug Zurampic to Grünenthal in Europe and Latin America
June 2, 2016Business Services, Manufacturing and Production, Sales and Marketing AstraZeneca, Grunenthal, Licencing, Zurampic, gout, sales
UK drugmaker AstraZeneca (LSE: AZN) on Thursday said it has entered into a licensing agreement worth up to $230 million …
AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals
April 27, 2016Research and Development, Sales and Marketing AstraZeneca, Ironwood, Licencing, Zurampic, agreement, exclusive, gout, lesinurad, sales
AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which will see the latter granted …
FDA approves AstraZeneca’s gout drug Zurampic
December 23, 2015Sales and Marketing AstraZeneca, FDA, Zurampic, gout, lensinurad
The US FDA has approved AstraZeneca’s Zurampic to treat high levels of uric acid in the blood. The drug is …
FDA backs AZ gout drug despite safety concerns
October 26, 2015Sales and Marketing AstraZeneca, Zurampic, gout, lesinurad
FDA reviewers have recommended approving AstraZeneca’s new gout therapy Zurampic, which the company purchased in a $1.3 billion buyout, despite …
AstraZeneca to buy Ardea for $1.3 billion
April 23, 2012Research and Development, Sales and Marketing Ardea, AstraZeneca, febuxostat, gout
AstraZeneca is to buy Ardea Biosciences for $1 billion to help bolster its pipeline. Under the terms of the agreement, …
Takeda to buy gout specialist URL Pharma for $800m
April 16, 2012Research and Development, Sales and Marketing R&D, Takeda, acquisition, gout
Takeda is set to purchase URL Pharmaceuticals for $800 million, helping offset the loss of its blockbuster ulcer drug Prevacid. …
Savient plays down gout drug manufacturing problems
January 11, 2011Manufacturing and Production, Sales and Marketing Krystexxa, Savient, biologic manufacturing, gout, manufacturing compliance, pegloticase
Savient Pharmaceuticals has reported that some production batches of Krystexxa, its recently-approved second-line treatment for gout, have failed to meet …
